The Longevity Fund is the first specialist venture capital fund created explicitly to invest only in companies extending human healthy lifespan and treating aging itself as a disease, founded and led by Laura Deming who began aging research at 12 and became one of the youngest fund managers in the U.S. Despite being a small seed/Series A vehicle, its companies have collectively raised over $1B and produced multiple IPOs, demonstrating that a focused aging thesis could generate mainstream biotech outcomes and helping legitimize longevity biotech as an investable category.